Alpharose Therapeutics Inc.
Publicly observedLeander, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Leander | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Alpharose Therapeutics Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | NEAQXBDXKMD7 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant20 Sept 2026Publicly observed
NIH SBIR/STTR award: Anti-Sense Oligonucleotide Therapy for HNRNPH2 Neurodevelopmental Disorder.
USD 313,208.00 · Eunice Kennedy Shriver National Institute of Child Health and Human Development · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.